ESC 365 - Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

ESC Professional Premium Access

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

Session: New perspectives in cardiology (1) - Lipids: drug therapy

Topic: Drug therapy

Speaker: Professor L. Rallidis (Athens, GR)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

0 follower

4 more presentations in this session

Discussant - Lipids: drug therapy

Suboptimal cardiovascular risk management in cancer survivors: analysis of statin prescription patterns following coronary calcium scoring

Speaker: Doctor C. Soh (Melbourne, AU)

Novel risk model for predicting incident atrial fibrillation in patients at high cardiovascular risk receiving omega-3 fatty acid: sub-analysis from the STRENGTH randomized clinical trial

Speaker: Doctor T. Wang (Cleveland, US)

Pleiotropic effects of inclisiran on arterial structural and functional parameters

Speaker: Doctor M. Bellomare (Milan, IT)

Access the full session

New perspectives in cardiology (1) - Lipids: drug therapy

Speakers: Professor L. Rallidis, Doctor C. Soh, Doctor T. Wang, Doctor M. Bellomare

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources